Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 2/20 | 0.37 |
| ▸ | JAK1 | P23458 | 2/20 | 0.37 |
| ▸ | ACACB | O00763 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19389951 | 1.00 | EPHX2 (0.38) | EPHX2JAK2JAK1ACACBUSP2 | |
| SCHEMBL30532870 | 0.86 | EPHX2 (0.37) | EPHX2JAK2JAK1ACACBUSP2 | |
| SCHEMBL23578904 | 0.86 | EPHX2 (0.37) | EPHX2JAK2JAK1ACACBUSP2 | |
| SCHEMBL31756246 | 0.86 | EPHX2 (0.37) | EPHX2JAK2JAK1ACACBUSP2 | |
| SCHEMBL25151395 | 0.84 | JAK2 (0.38) | EPHX2JAK2JAK1ACACBUSP2 | |
| SCHEMBL22064291 | 0.84 | CHRM2 (0.38) | EPHX2USP2SMN1; SMN2HSD17B10KDM1A | |
| SCHEMBL14310674 | 0.83 | CHRM2 (0.37) | EPHX2USP2SMN1; SMN2HSD17B10CHRM2 | |
| SCHEMBL28725753 | 0.83 | JAK2 (0.38) | EPHX2JAK2JAK1ACACBUSP2 | |
| SCHEMBL28558549 | 0.83 | JAK2 (0.38) | EPHX2JAK2JAK1ACACBUSP2 | |
| SCHEMBL15054838 | 0.83 | EPHX2 (0.37) | EPHX2JAK2JAK1ACACBUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787785-B2 | Pyrazolopyridine derivatives and uses thereof | NOVARTIS AG (CH) | 2023-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11787785-B2 | Pyrazolopyridine derivatives and uses thereof | HBZ, ZFX, WIZ | EPHX2 2949/4885JAK2 811/4885JAK1 3278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.